General Psychiatry - Articles - Page 86

Prescription CBD Is Available, But Are We Ready to Use It?

January 1, 2019

Chris Aiken, MD Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Your patient comes in with a new medication on his list: CBD oil. He started taking it for anxiety and wants to know if it’s safe. You hedge, explaining that there is limited information available on unregulated products, but the patient is persistent. He says CBD oil is available as a prescription, and wonders if you could write one for it.

Deprescribing Medication

January 1, 2019

Barbara Farrell, PharmD

Barbara Farrell, PharmD

Assistant Professor, Department of Family Medicine, University of Ottawa and Adjunct Assistant Professor, School of Pharmacy, University of Waterloo. Co-founder of the Canadian Deprescribing Network. Dr. Farrell has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Deprescribing refers to lowering or stopping medications that might be causing harm or no longer providing benefit. It’s done in a planned, collaborative, and supervised way rather than simply the patient stopping the medications independently.

Wellbutrin Augmentation: When Does It Work?

January 1, 2019

Chris Aiken, MD

Chris Aiken, MD Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Dear Dr. Aiken: In the July/August 2018 issue, you wrote that bupropion (Wellbutrin) augmentation does not work in treatment-resistant depression (TRD). So why do we see it work so often in practice?

Cannabidiol for Schizophrenia

January 1, 2019

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this pilot study, investigators evaluated the benefits of cannabidiol (CBD), which is one of the two main active components of marijuana (the other being THC), for the treatment of schizophrenia.

Is Ketamine Just Another Opiate?

January 1, 2019

Michael Posternak, MD.

Michael Posternak, MD. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Ketamine’s rapid antidepressant effects have now been demonstrated in over two dozen double-blind, placebo-controlled trials, but how it works is less clear. For many years, NMDA receptor antagonism was thought responsible, but other NMDA antagonists have not worked well in depression.

Brexanolone: A New Treatment for Postpartum Depression

January 1, 2019

Chris Aiken, MD

Chris Aiken, MD Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There is a need for rapid treatment in postpartum depression, as each month of this potentially severe condition can take a toll on infant development. That is why brexanolone (Zulresso), which was recently fast-tracked for approval by the FDA, is causing such a splash.

CME Post-Test - Deprescribing, TCPR, January 2019

January 1, 2019

The post-test for this issue is available for one year after the publication date to subscribers only. By successfully completing the test you will be awarded a certificate for 1 CME credit.